ES2751761T3 - Compuestos de pirrol como inhibidores de proteínas cinasas ERK y composiciones farmacéuticas que contienen esos compuestos - Google Patents
Compuestos de pirrol como inhibidores de proteínas cinasas ERK y composiciones farmacéuticas que contienen esos compuestos Download PDFInfo
- Publication number
- ES2751761T3 ES2751761T3 ES17184079T ES17184079T ES2751761T3 ES 2751761 T3 ES2751761 T3 ES 2751761T3 ES 17184079 T ES17184079 T ES 17184079T ES 17184079 T ES17184079 T ES 17184079T ES 2751761 T3 ES2751761 T3 ES 2751761T3
- Authority
- ES
- Spain
- Prior art keywords
- acid
- pharmaceutically acceptable
- compound
- disorder
- carcinoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 0 CC[C@](C)Nc(nc1)cc(C2C=*(C(N[C@](CO)c3cccc(Cl)c3)=O)NC2)c1Cl Chemical compound CC[C@](C)Nc(nc1)cc(C2C=*(C(N[C@](CO)c3cccc(Cl)c3)=O)NC2)c1Cl 0.000 description 3
- RRPBMQVXLRPHHH-OAQYLSRUSA-N CC(C)CNc1cc(-c2c[nH]c(C(N[C@H](CO)c3cc(Cl)ccc3)=O)c2)c(C)cn1 Chemical compound CC(C)CNc1cc(-c2c[nH]c(C(N[C@H](CO)c3cc(Cl)ccc3)=O)c2)c(C)cn1 RRPBMQVXLRPHHH-OAQYLSRUSA-N 0.000 description 1
- KSERXGMCDHOLSS-LJQANCHMSA-N CC(C)Nc(nc1)cc(-c2c[nH]c(C(N[C@H](CO)c3cccc(Cl)c3)=O)c2)c1Cl Chemical compound CC(C)Nc(nc1)cc(-c2c[nH]c(C(N[C@H](CO)c3cccc(Cl)c3)=O)c2)c1Cl KSERXGMCDHOLSS-LJQANCHMSA-N 0.000 description 1
- JMRBTHGMBQQAQI-LJQANCHMSA-N CC(C)Nc(nc1)cc(-c2c[nH]c(C(N[C@H](CO)c3ccccc3)=O)c2)c1Cl Chemical compound CC(C)Nc(nc1)cc(-c2c[nH]c(C(N[C@H](CO)c3ccccc3)=O)c2)c1Cl JMRBTHGMBQQAQI-LJQANCHMSA-N 0.000 description 1
- JWHARJYOXFZWBE-PZJWPPBQSA-N CC[C@@H](C(O)=C)Nc(cc1-c2c[nH]c(C(N[C@H](CO)c3cc(Cl)ccc3)=O)c2)ncc1Cl Chemical compound CC[C@@H](C(O)=C)Nc(cc1-c2c[nH]c(C(N[C@H](CO)c3cc(Cl)ccc3)=O)c2)ncc1Cl JWHARJYOXFZWBE-PZJWPPBQSA-N 0.000 description 1
- IEUNVNVOKYGWOC-OXJNMPFZSA-N CC[C@@H](C=O)Nc(nc1)cc(-c2c[nH]c(C(N[C@H](CO)c3ccccc3)=O)c2)c1Cl Chemical compound CC[C@@H](C=O)Nc(nc1)cc(-c2c[nH]c(C(N[C@H](CO)c3ccccc3)=O)c2)c1Cl IEUNVNVOKYGWOC-OXJNMPFZSA-N 0.000 description 1
- KLIMNIZUYRYZSA-OXJNMPFZSA-N CC[C@@H](CO)Nc(nc1)cc(-c2c[nH]c(C(N[C@H](CO)c3cccc(Cl)c3)=O)c2)c1Cl Chemical compound CC[C@@H](CO)Nc(nc1)cc(-c2c[nH]c(C(N[C@H](CO)c3cccc(Cl)c3)=O)c2)c1Cl KLIMNIZUYRYZSA-OXJNMPFZSA-N 0.000 description 1
- XHQNBLCPPZUSJW-RNODOKPDSA-N CC[C@H](C)Nc(nc1)cc(-c2c[nH]c(C(N[C@H](CO)c3cc(Cl)ccc3)=O)c2)c1Cl Chemical compound CC[C@H](C)Nc(nc1)cc(-c2c[nH]c(C(N[C@H](CO)c3cc(Cl)ccc3)=O)c2)c1Cl XHQNBLCPPZUSJW-RNODOKPDSA-N 0.000 description 1
- QYNWGYRXWMESGD-VPHZQHATSA-N C[C@@H](CO)NC(N=CC1Cl)=CC1c1c[nH]c(C(N[C@H](CO)c2cc(Cl)ccc2)=O)c1 Chemical compound C[C@@H](CO)NC(N=CC1Cl)=CC1c1c[nH]c(C(N[C@H](CO)c2cc(Cl)ccc2)=O)c1 QYNWGYRXWMESGD-VPHZQHATSA-N 0.000 description 1
- GTHABLUBVWETMU-ORAYPTAESA-N C[C@@H](CO)Nc(nc1)cc(-c2c[nH]c(C(N[C@H](CO)c3ccccc3)=O)c2)c1Cl Chemical compound C[C@@H](CO)Nc(nc1)cc(-c2c[nH]c(C(N[C@H](CO)c3ccccc3)=O)c2)c1Cl GTHABLUBVWETMU-ORAYPTAESA-N 0.000 description 1
- ZSHNJVODPUMBER-HXUWFJFHSA-N Cc(cnc(NC1CC1)c1)c1-c1c[nH]c(C(N[C@H](CO)c2cc(Cl)ccc2)=O)c1 Chemical compound Cc(cnc(NC1CC1)c1)c1-c1c[nH]c(C(N[C@H](CO)c2cc(Cl)ccc2)=O)c1 ZSHNJVODPUMBER-HXUWFJFHSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57130904P | 2004-05-14 | 2004-05-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2751761T3 true ES2751761T3 (es) | 2020-04-01 |
Family
ID=35106760
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17184079T Expired - Lifetime ES2751761T3 (es) | 2004-05-14 | 2005-05-13 | Compuestos de pirrol como inhibidores de proteínas cinasas ERK y composiciones farmacéuticas que contienen esos compuestos |
| ES19199330T Expired - Lifetime ES2897422T3 (es) | 2004-05-14 | 2005-05-13 | Compuestos pirroles como inhibidores de proteínas cinasas ERK y composiciones farmacéuticas que contienen esos compuestos |
| ES05748073.3T Expired - Lifetime ES2513965T3 (es) | 2004-05-14 | 2005-05-13 | Compuestos pirroles como inhibidores de proteínas cinasas ERK y composiciones farmacéuticas que contienen esos compuestos |
| ES14163944.3T Expired - Lifetime ES2651439T3 (es) | 2004-05-14 | 2005-05-13 | Compuestos de pirrol como inhibidores de proteínas cinasas ERK y composiciones farmacéuticas que contienen esos compuestos |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES19199330T Expired - Lifetime ES2897422T3 (es) | 2004-05-14 | 2005-05-13 | Compuestos pirroles como inhibidores de proteínas cinasas ERK y composiciones farmacéuticas que contienen esos compuestos |
| ES05748073.3T Expired - Lifetime ES2513965T3 (es) | 2004-05-14 | 2005-05-13 | Compuestos pirroles como inhibidores de proteínas cinasas ERK y composiciones farmacéuticas que contienen esos compuestos |
| ES14163944.3T Expired - Lifetime ES2651439T3 (es) | 2004-05-14 | 2005-05-13 | Compuestos de pirrol como inhibidores de proteínas cinasas ERK y composiciones farmacéuticas que contienen esos compuestos |
Country Status (25)
| Country | Link |
|---|---|
| US (6) | US7354939B2 (enExample) |
| EP (5) | EP3608315B1 (enExample) |
| JP (1) | JP5132305B2 (enExample) |
| CN (1) | CN1976919A (enExample) |
| AR (2) | AR051735A1 (enExample) |
| AU (1) | AU2005245885B2 (enExample) |
| BR (1) | BRPI0511111A (enExample) |
| CA (1) | CA2566461C (enExample) |
| CY (1) | CY1122336T1 (enExample) |
| DK (1) | DK3305776T3 (enExample) |
| ES (4) | ES2751761T3 (enExample) |
| HU (1) | HUE047130T2 (enExample) |
| IL (1) | IL179207A0 (enExample) |
| LT (1) | LT3305776T (enExample) |
| MX (1) | MXPA06013209A (enExample) |
| NO (1) | NO20065727L (enExample) |
| NZ (1) | NZ551582A (enExample) |
| PL (1) | PL3305776T3 (enExample) |
| PT (1) | PT3305776T (enExample) |
| RU (1) | RU2376299C2 (enExample) |
| SI (1) | SI3305776T1 (enExample) |
| TW (1) | TW200607803A (enExample) |
| UA (1) | UA84930C2 (enExample) |
| WO (1) | WO2005113541A1 (enExample) |
| ZA (1) | ZA200609975B (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004221881A1 (en) * | 2003-03-13 | 2004-09-30 | Vertex Pharmaceuticals Incorporated | Compositions useful as protein kinase inhibitors |
| EP1730134A1 (en) * | 2004-03-26 | 2006-12-13 | Vertex Pharmaceuticals Incorporated | Pyridine inhibitors of erk2 and uses thereof |
| ES2751761T3 (es) * | 2004-05-14 | 2020-04-01 | Vertex Pharma | Compuestos de pirrol como inhibidores de proteínas cinasas ERK y composiciones farmacéuticas que contienen esos compuestos |
| US8546404B2 (en) | 2005-12-13 | 2013-10-01 | Merck Sharp & Dohme | Compounds that are ERK inhibitors |
| KR20080103996A (ko) * | 2006-02-16 | 2008-11-28 | 쉐링 코포레이션 | Ｅｒｋ 억제제로서 피롤리딘 유도체 |
| CN101815711A (zh) * | 2007-06-05 | 2010-08-25 | 先灵公司 | 多环吲唑衍生物及其作为erk抑制剂治疗癌症的用途 |
| US8716483B2 (en) | 2008-02-21 | 2014-05-06 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
| CN102146074B (zh) * | 2011-01-26 | 2013-02-06 | 江苏先声药物研究有限公司 | 吡咯衍生物的制备方法及应用 |
| WO2012172093A1 (en) | 2011-06-17 | 2012-12-20 | Merz Pharma Gmbh & Co. Kgaa | Dihydroindolizine derivate as metabotropic glutamate receptor modulators |
| AU2014337504B2 (en) | 2013-10-14 | 2020-01-30 | Indiana University Research And Technology Corporation | Use of acamprosate to modulate ERK 1-2 activation in animal models for FXS and ASD and individuals diagnosed with FXS and ASD |
| EP3061754A4 (en) | 2013-10-23 | 2017-03-22 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| WO2015095838A2 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Cancer treatments using combinations of mek type i and erk inhibitors |
| WO2015095835A1 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Methods of modulating radioiodine uptake for the treatment of radioiodine-refractory cancers |
| AU2014368912B2 (en) * | 2013-12-20 | 2020-04-30 | Biomed Valley Discoveries, Inc. | Cancer treatments using combinations of type 2 MEK and ERK inhibitors |
| WO2015095833A1 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Treatment of hematologic cancers |
| WO2015095831A1 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Cancer treatments using combinations of mtor and erk inhibitors |
| ES3033810T3 (en) | 2013-12-20 | 2025-08-08 | Biomed Valley Discoveries Inc | Cancer treatments using combinations of cdk and erk inhibitors |
| WO2015095807A1 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Cancer treatments using combinations of egfr and erk inhibitors |
| MX394252B (es) | 2013-12-20 | 2025-03-21 | Biomed Valley Discoveries Inc | Tratamiento del cancer usando combinaciones de inhibidores de erk y raf |
| WO2015095842A2 (en) | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers |
| EP3082957B1 (en) * | 2013-12-20 | 2022-04-06 | Biomed Valley Discoveries, Inc. | Cancer treatments using combinations of pi3k/akt pathway and erk inhibitors |
| CA2975116C (en) * | 2015-01-30 | 2022-10-11 | Biomed Valley Discoveries, Inc. | Crystalline c21h22c12n4o2 malonate |
| CA3218488A1 (en) | 2015-01-30 | 2016-08-04 | Biomed Valley Discoveries, Inc. | Crystalline forms of c21h22ci2n4o2 |
| WO2016187028A1 (en) * | 2015-05-15 | 2016-11-24 | Celgene Avilomics Research, Inc. | Heteroaryl compounds, synthesis thereof, and intermediates thereto |
| CA2987963C (en) * | 2015-06-03 | 2023-01-24 | Js Innopharm (Shanghai) Ltd. | Heterocyclic compounds for treating psoriasis |
| WO2016192063A1 (en) * | 2015-06-03 | 2016-12-08 | Changzhou Jiekai Pharmatech Co. Ltd | Heterocyclic compounds as erk inhibitors |
| MX382927B (es) | 2015-10-21 | 2025-03-13 | Otsuka Pharma Co Ltd | Compuestos de benzolactama como inhibidores de la proteína cinasa. |
| EP3170822A1 (en) | 2015-11-18 | 2017-05-24 | AGV Discovery | Azaindole derivatives and their use as erk kinase inhibitors |
| CN109890827A (zh) * | 2016-10-05 | 2019-06-14 | 芝诺罗耶尔蒂里程碑有限责任公司 | 螺环化合物 |
| GB201706327D0 (en) | 2017-04-20 | 2017-06-07 | Otsuka Pharma Co Ltd | A pharmaceutical compound |
| EP3694518A1 (en) * | 2017-10-12 | 2020-08-19 | Novartis AG | Combinations of mdm2 inhibitors with inhibitors of erk for treating cancers |
| WO2019180141A1 (en) | 2018-03-23 | 2019-09-26 | Bayer Aktiengesellschaft | Combinations of rogaratinib |
| WO2020223177A1 (en) * | 2019-04-29 | 2020-11-05 | The Board Of Trustees Of The University Of Illinois | Mek inhibitors for corneal scarring and neovascularization |
| WO2021020841A1 (en) * | 2019-07-29 | 2021-02-04 | Standigm Inc. | Composition for preventing or treating metabolic liver disease |
| EP4212531A1 (en) | 2022-01-14 | 2023-07-19 | AGV Discovery | Azaindole derivatives and their use as erk kinase inhibitors |
| CN118765276A (zh) * | 2022-03-08 | 2024-10-11 | 甘李药业股份有限公司 | 氘代化合物，及其制备方法和应用 |
| MX2024011415A (es) * | 2022-03-24 | 2024-09-24 | Biomed Valley Discoveries Inc | Analogos deuterados de inhibidores de pirrol de cinasa regulada por se?ales extracelulares (erk), sintesis de los mismos e intermediarios de los mismos. |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
| US5565413A (en) * | 1994-12-06 | 1996-10-15 | Zeneca Limited | Substituted pyridyl phenyl ketone herbicides |
| US5472966A (en) * | 1995-03-29 | 1995-12-05 | Bristol-Myers Squibb Company | Antidepressant heteroarylaminoalkyl derivatives of naphthyl-monazines |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| DK1178981T3 (da) * | 1999-05-14 | 2003-09-29 | Ortho Mcneil Pharm Inc | Substituerede 3-pyridyl-4-arylpyrroler og deres terapeutiske og profylaktiske anvendelser |
| DE60027718T2 (de) | 1999-06-22 | 2007-05-16 | Takeda Pharmaceutical Co. Ltd. | Acylhydrazinderivate, verfahren zu ihrer herstellung und ihre verwendung |
| MY130778A (en) * | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
| WO2003091246A1 (en) | 2002-04-26 | 2003-11-06 | Vertex Pharmaceuticals Incorporated | Pyrrole derivatives as inhibitors of erk2 and uses thereof |
| JP4570955B2 (ja) * | 2002-07-09 | 2010-10-27 | バーテクス ファーマスーティカルズ インコーポレイテッド | プロテインキナーゼ阻害活性を持つイミダゾール類 |
| ES2575522T3 (es) * | 2002-07-18 | 2016-06-29 | Janssen Pharmaceutica Nv | Inhibidores de quinasas con triazina sustituida |
| GB0217780D0 (en) * | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Compounds |
| BR0313397A (pt) * | 2002-08-14 | 2005-06-28 | Vertex Pharmaceuticals Incorpo | Inibidores de proteina cinase e usos destes |
| AU2004221881A1 (en) | 2003-03-13 | 2004-09-30 | Vertex Pharmaceuticals Incorporated | Compositions useful as protein kinase inhibitors |
| ES2751761T3 (es) * | 2004-05-14 | 2020-04-01 | Vertex Pharma | Compuestos de pirrol como inhibidores de proteínas cinasas ERK y composiciones farmacéuticas que contienen esos compuestos |
-
2005
- 2005-05-13 ES ES17184079T patent/ES2751761T3/es not_active Expired - Lifetime
- 2005-05-13 NZ NZ551582A patent/NZ551582A/en not_active IP Right Cessation
- 2005-05-13 CN CNA200580021418XA patent/CN1976919A/zh active Pending
- 2005-05-13 ES ES19199330T patent/ES2897422T3/es not_active Expired - Lifetime
- 2005-05-13 EP EP19199330.2A patent/EP3608315B1/en not_active Expired - Lifetime
- 2005-05-13 PT PT171840796T patent/PT3305776T/pt unknown
- 2005-05-13 DK DK17184079T patent/DK3305776T3/da active
- 2005-05-13 AR ARP050101987A patent/AR051735A1/es not_active Application Discontinuation
- 2005-05-13 EP EP05748073.3A patent/EP1753738B1/en not_active Expired - Lifetime
- 2005-05-13 TW TW094115644A patent/TW200607803A/zh unknown
- 2005-05-13 HU HUE17184079A patent/HUE047130T2/hu unknown
- 2005-05-13 MX MXPA06013209A patent/MXPA06013209A/es active IP Right Grant
- 2005-05-13 ES ES05748073.3T patent/ES2513965T3/es not_active Expired - Lifetime
- 2005-05-13 ZA ZA200609975A patent/ZA200609975B/en unknown
- 2005-05-13 LT LTEP17184079.6T patent/LT3305776T/lt unknown
- 2005-05-13 RU RU2006144445/04A patent/RU2376299C2/ru active
- 2005-05-13 PL PL17184079T patent/PL3305776T3/pl unknown
- 2005-05-13 CA CA2566461A patent/CA2566461C/en not_active Expired - Lifetime
- 2005-05-13 EP EP14163944.3A patent/EP2799434B1/en not_active Expired - Lifetime
- 2005-05-13 BR BRPI0511111-0A patent/BRPI0511111A/pt not_active IP Right Cessation
- 2005-05-13 SI SI200532267T patent/SI3305776T1/sl unknown
- 2005-05-13 ES ES14163944.3T patent/ES2651439T3/es not_active Expired - Lifetime
- 2005-05-13 EP EP17184079.6A patent/EP3305776B1/en not_active Expired - Lifetime
- 2005-05-13 UA UAA200613208A patent/UA84930C2/ru unknown
- 2005-05-13 WO PCT/US2005/016902 patent/WO2005113541A1/en not_active Ceased
- 2005-05-13 AU AU2005245885A patent/AU2005245885B2/en not_active Expired
- 2005-05-13 US US11/128,870 patent/US7354939B2/en not_active Ceased
- 2005-05-13 EP EP21190432.1A patent/EP3943489A1/en active Pending
- 2005-05-13 JP JP2007513432A patent/JP5132305B2/ja not_active Expired - Lifetime
-
2006
- 2006-11-13 IL IL179207A patent/IL179207A0/en unknown
- 2006-12-12 NO NO20065727A patent/NO20065727L/no not_active Application Discontinuation
-
2013
- 2013-08-23 US US14/544,396 patent/USRE46097E1/en not_active Expired - Lifetime
-
2016
- 2016-06-28 US US15/195,021 patent/USRE47318E1/en not_active Expired - Lifetime
- 2016-11-18 AR ARP160103545A patent/AR106755A2/es active IP Right Grant
-
2019
- 2019-03-25 US US16/363,905 patent/USRE48266E1/en not_active Expired - Lifetime
- 2019-12-03 CY CY20191101265T patent/CY1122336T1/el unknown
-
2020
- 2020-10-15 US US17/071,566 patent/USRE49500E1/en not_active Expired - Lifetime
-
2023
- 2023-02-22 US US18/173,004 patent/US20230183276A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2751761T3 (es) | Compuestos de pirrol como inhibidores de proteínas cinasas ERK y composiciones farmacéuticas que contienen esos compuestos | |
| EP1753744B1 (en) | Prodrugs of pyrrolylpyrimidine erk protein kinase inhibitors | |
| HK40064501A (en) | Pyrrole inhibitors of erk protein kinase, synthesis thereof and intermediates thereto | |
| HK40021464A (en) | Pyrrole compounds as inhibitors of erk protein kinases and pharmaceutical compositions containing these compounds | |
| HK40021464B (en) | Pyrrole compounds as inhibitors of erk protein kinases and pharmaceutical compositions containing these compounds | |
| HK1247910B (en) | Pyrrole compounds as inhibitors of erk protein kinases and pharmaceutical compositions containing these compounds | |
| HK1203505B (en) | Pyrrole compounds as inhibitors of erk protein kinases and pharmaceutical compositions containing these compounds | |
| KR20070031934A (ko) | Ｅｒｋ 단백질 키나아제의 억제제로서의 피롤 화합물, 이의합성 및 이의 중간체 |